Navigation Links
Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
Date:8/28/2008

SAN DIEGO, Aug. 28 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the NewsMakers in the Biotech Industry Conference on September 4, 2008 at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) at the Millennium Broadway Hotel in New York City. Jack Lief, Arena's President and Chief Executive Officer, is scheduled to provide an overview of the company, including its clinical development and discovery programs.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at http://www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

For
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
2. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
3. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
4. ThreeWire Expands Presence in the Pharmaceutical Arena
5. Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
6. Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
7. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
9. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
10. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... (PRWEB) September 18, 2014 Leatherwood ... FM-4910 listed material, to stay competitive in the ... These high-performance materials ultimately impact product quality and ... and owner. , Established in 1980 in Lewisville, ... as many fabricators have left the business. Much ...
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire/ - Oncothyreon Inc. ... of previously announced concurrent but separate underwritten offerings of ... to the public of $2.00 per share, for expected ... its Series A Convertible Preferred Stock at a price ... gross proceeds of $20 million. Each share of Series ...
(Date:9/18/2014)... September 18, 2014 SeqLL Inc., ... (tSMS™) technology, announced today the closing of a ... led by Genomic Diagnostic Technologies, will increase the ... applications. , Founded in March 2013 by Daniel ... Analyst at Helicos BioSciences, SeqLL has continued to ...
(Date:9/18/2014)... developed a new microscopy technology that allows them ... higher-than-ever resolution. , Dubbed "Complementation Activated Light Microscopy" ... are an order of magnitude finer than conventional ... of biomolecules at the nanometer scale. , In ... Nature Communications , the researchers behind CALM used ...
Breaking Biology Technology:Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2Scientists pioneer microscopy technique that yields fresh data on muscular dystrophy 2
... of revenue growth ... 2007 Highlights: * Product ... SET pulse oximeter units increase 20% to 116,300 units, IRVINE, Calif., Feb. ... Measure-Through,Motion & Low Perfusion pulse oximetry, today announced its financial,results for both the ...
... Replidyne, Inc.,(Nasdaq: RDYN ) today announced its financial results ... Replidyne reported a net loss of $16.9 million for ... per basic and diluted common share,of $0.63 per share, compared ... and diluted common share, for the quarter ended December 31, ...
... Market Research,a global provider of pharmaceutical competitive intelligence ... critical strategic insight,for pharma and biotech companies with ... therapies., In this report, entitled MedPredict Thought ... global Thought Leader Panel,debates tough questions facing drug ...
Cached Biology Technology:Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 2Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 3Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 4Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 5Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 6Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 7Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 8Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 9Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 10Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 11Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 12Replidyne Announces 2007 Fourth Quarter and Full Year Results 2Replidyne Announces 2007 Fourth Quarter and Full Year Results 3Replidyne Announces 2007 Fourth Quarter and Full Year Results 4Replidyne Announces 2007 Fourth Quarter and Full Year Results 5Replidyne Announces 2007 Fourth Quarter and Full Year Results 6Replidyne Announces 2007 Fourth Quarter and Full Year Results 7Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report 2
(Date:9/18/2014)... icy moon of Uranus, is one of the most ... Despite its relatively small size, Miranda appears to have ... the formation of at least three remarkable and unique ... These coronae are visible in Miranda,s southern hemisphere, and ... corona, the largest, has ridges and troughs with up ...
(Date:9/18/2014)... University and the Quebec government have discovered microplastics ... Journal of Fisheries and Aquatic Sciences . , ... or industrial cleansers, to which they are commonly ... and buoyancy, they may readily pass through sewage ... in the world,s oceans, but have only recently ...
(Date:9/18/2014)... The fall foliage season that prompts millions of Americans to ... later and possibly last a little longer within a century, ... leaf peeping in some areas of the United States as ... report in the journal Global Ecology and Biogeography . ... that is the state tree of New Hampshire could ...
Breaking Biology News(10 mins):Miranda: An icy moon deformed by tidal heating 2Miranda: An icy moon deformed by tidal heating 3Miranda: An icy moon deformed by tidal heating 4Miranda: An icy moon deformed by tidal heating 5Miranda: An icy moon deformed by tidal heating 6Miranda: An icy moon deformed by tidal heating 7Microplastic pollution discovered in St. Lawrence River sediments 2Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4
... the laboratory of Assistant Professor Frank J. Slack at Yale ... is regulated in lung cancer, presenting new possibilities for diagnosis ... the journals Cell and Developmental Cell. , The oncogene Ras ... where it is over-expressed or activated by mutation. According to ...
... prevented allergic reactions in laboratory mice, as well as ... California, Los Angeles (UCLA) researchers report in the April ... future, the investigators say, these promising results could lead ... allergies, but also possibly for severe food allergies such ...
... dead bone of a transplanted skeletal graft into living tissue ... therapy to stimulate the body into treating the foreign splint ... of cancer and trauma patients each year who suffer with ... Feb. 13 and will appear in the March 1 issue ...
Cached Biology News:Yale Scientists Find MicroRNA Regulates Ras Cancer Gene 2Novel Therapy Tested in Mice Could Chase Away Cat Allergies 2Novel Therapy Tested in Mice Could Chase Away Cat Allergies 3Gene therapy converts dead bone graft to new, living tissue 2Gene therapy converts dead bone graft to new, living tissue 3Gene therapy converts dead bone graft to new, living tissue 4
Mouse monoclonal antibody raised against a partial recombinant PRKG1. NCBI Entrez Gene ID = PRKG1...
... polyclonal antibody raised against a ... Immunogen: PPP4C (NP_002711, ... partial recombinant protein with GST ... Number: NM_002720 ...
Mouse monoclonal antibody raised against a full length recombinant GPT. NCBI Entrez Gene ID = GPT...
Mouse monoclonal antibody raised against a partial recombinant CAPG. NCBI Entrez Gene ID = CAPG...
Biology Products: